The role of biomarkers and dosimetry parameters in overall and progression free survival prediction for patients treated with personalized 90Y glass microspheres SIRT: a preliminary machine learning study

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209–49.

Article  Google Scholar 

Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004;127(5):S5–16.

Article  PubMed  Google Scholar 

Lau W, Leung W, Ho S, Leung N, Chan M, Lin J, et al. Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II study. Br J Cancer. 1994;70(5):994–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dancey JE, Shepherd FA, Paul K, Sniderman KW, Houle S, Gabrys J, et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med. 2000;41(10):1673–81.

CAS  PubMed  Google Scholar 

Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2010;138(1):52–64.

Article  CAS  PubMed  Google Scholar 

Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology. 2011;54(3):868–78.

Article  PubMed  Google Scholar 

Garin E, Rolland Y, Laffont S, Edeline J. Clinical impact of 99m Tc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with 90 Y-loaded microspheres. Eur J Nucl Med Mol Imaging. 2016;43:559–75.

Article  CAS  PubMed  Google Scholar 

Lau W-Y, Kennedy AS, Kim YH, Lai HK, Lee R-C, Leung TW, et al. Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres. Int J Radiat Oncol Biol Phys. 2012;82(1):401–7.

Article  PubMed  Google Scholar 

Sangro B, Iñarrairaegui M, Bilbao JI. Radioembolization for hepatocellular carcinoma. J Hepatol. 2012;56(2):464–73.

Article  PubMed  Google Scholar 

Chiesa C, Sjogreen-Gleisner K, Walrand S, Strigari L, Flux G, Gear J, et al. EANM dosimetry committee series on standard operational procedures: a unified methodology for 99m Tc-MAA pre-and 90 Y peri-therapy dosimetry in liver radioembolization with 90 Y microspheres. EJNMMI Phys. 2021;8:1–44.

Article  Google Scholar 

Levillain H, Bagni O, Deroose CM, Dieudonné A, Gnesin S, Grosser OS, et al. International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres. Eur J Nucl Med Mol Imaging. 2021;48:1570–84.

Article  PubMed  PubMed Central  Google Scholar 

Flamen P, Vanderlinden B, Delatte P, Ghanem G, Ameye L, Van Den Eynde M, et al. Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labeled resin microspheres. Phys Med Biol. 2008;53(22):6591.

Article  PubMed  Google Scholar 

Levillain H, Duran Derijckere I, Marin G, Guiot T, Vouche M, Reynaert N, et al. 90 Y-PET/CT-based dosimetry after selective internal radiation therapy predicts outcome in patients with liver metastases from colorectal cancer. EJNMMI Res. 2018;8:1–9.

Article  CAS  Google Scholar 

van den Hoven AF, Rosenbaum CE, Elias SG, de Jong HW, Koopman M, Verkooijen HM, et al. Insights into the dose–response relationship of radioembolization with resin 90Y-microspheres: a prospective cohort study in patients with colorectal cancer liver metastases. J Nucl Med. 2016;57(7):1014–9.

Article  PubMed  Google Scholar 

Fowler KJ, Maughan NM, Laforest R, Saad NE, Sharma A, Olsen J, et al. PET/MRI of hepatic 90Y microsphere deposition determines individual tumor response. Cardiovasc Interv Radiol. 2016;39:855–64.

Article  Google Scholar 

Strigari L, Sciuto R, Rea S, Carpanese L, Pizzi G, Soriani A, et al. Efficacy and toxicity related to treatment of hepatocellular carcinoma with 90Y-SIR spheres: radiobiologic considerations. J Nucl Med. 2010;51(9):1377–85.

Article  CAS  PubMed  Google Scholar 

Chapiro J, Duran R, Lin M, Schernthaner R, Lesage D, Wang Z, et al. Early survival prediction after intra-arterial therapies: a 3D quantitative MRI assessment of tumour response after TACE or radioembolization of colorectal cancer metastases to the liver. Eur Radiol. 2015;25:1993–2003.

Article  PubMed  PubMed Central  Google Scholar 

Gonzalez-Guindalini FD, Botelho MP, Harmath CB, Sandrasegaran K, Miller FH, Salem R, et al. Assessment of liver tumor response to therapy: role of quantitative imaging. Radiographics. 2013;33(6):1781–800.

Article  PubMed  Google Scholar 

Laubender RP, Lynghjem J, D’Anastasi M, Heinemann V, Modest DP, Mansmann UR, et al. Evaluating the agreement between tumour volumetry and the estimated volumes of tumour lesions using an algorithm. Eur Radiol. 2014;24:1521–8.

Article  PubMed  Google Scholar 

Riaz A, Salem R. Laboratory and imaging prognostic indicators following arterial locoregional therapies for hepatocellular carcinoma survival. J Vasc Interv Radiol. 2019;30(12):1893–4.

Article  PubMed  Google Scholar 

Qaseem Y, Salem R. Observing durable responses and a prolonged survival tail in advanced hepatocellular carcinoma with portal vein invasion treated with Y90 radioembolization. Cardiovasc Interv Radiol. 2020;43:1423–4.

Article  Google Scholar 

Gao R, Gabr A, Mouli S, Riaz A, Kulik L, Lewandowski RJ, et al. Toxicity and survival of hepatocellular carcinoma patients with hepatitis B infection treated with yttrium-90 radioembolization: an updated 15-year study. J Vasc Interv Radiol. 2020;31(3):401–8. e1.

Article  PubMed  Google Scholar 

Miller MD, Sze DY, Padia SA, Lewandowski RJ, Salem R, Mpofu P, et al. Response and overall survival for Yttrium-90 radioembolization of hepatic sarcoma: a multicenter retrospective study. J Vasc Interv Radiol. 2018;29(6):867–73.

Article  PubMed  Google Scholar 

Gordon AC, Gabr A, Riaz A, Uddin OM, Abouchaleh N, Ali R, et al. Radioembolization super survivors: extended survival in non-operative hepatocellular carcinoma. Cardiovasc Interv Radiol. 2018;41:1557–65.

Article  Google Scholar 

Ghosn M, Derbel H, Kharrat R, Oubaya N, Mulé S, Chalaye J, et al. Prediction of overall survival in patients with hepatocellular carcinoma treated with Y-90 radioembolization by imaging response criteria. Diagn Interv Imaging. 2021;102(1):35–44.

Article  CAS  PubMed  Google Scholar 

Chen JX, Rose S, White SB, El-Haddad G, Fidelman N, Yarmohammadi H, et al. Embolotherapy for neuroendocrine tumor liver metastases: prognostic factors for hepatic progression-free survival and overall survival. Cardiovasc Interv Radiol. 2017;40:69–80.

Article  Google Scholar 

Mähringer-Kunz A, Steinle V, Kloeckner R, Schotten S, Hahn F, Schmidtmann I, et al. The impact of portal vein tumor thrombosis on survival in patients with hepatocellular carcinoma treated with different therapies: a cohort study. PLoS ONE. 2021;16(5):e0249426.

Article  PubMed  PubMed Central  Google Scholar 

Lee BQ, Abbott EM, Able S, Thompson JM, Hill MA, Kartsonaki C, et al. Radiosensitivity of colorectal cancer to 90Y and the radiobiological implications for radioembolisation therapy. Phys Med Biol. 2019;64(13):135018.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gholami YH, Willowson KP, Forwood NJ, Harvie R, Hardcastle N, Bromley R, et al. Comparison of radiobiological parameters for 90Y radionuclide therapy (RNT) and external beam radiotherapy (EBRT) in vitro. EJNMMI Phys. 2018;5(1):1–19.

Article  Google Scholar 

Högberg J, Rizell M, Hultborn R, Svensson J, Henrikson O, Mölne J, et al. Increased absorbed liver dose in Selective Internal Radiation Therapy (SIRT) correlates with increased sphere-cluster frequency and absorbed dose inhomogeneity. EJNMMI Phys. 2015;2:1–17.

Article  Google Scholar 

Garin E, Tselikas L, Guiu B, Chalaye J, Edeline J, de Baere T, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6(1):17–29.

Article  PubMed  Google Scholar 

Garin E, Rolland Y, Edeline J, Icard N, Lenoir L, Laffont S, et al. Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis. J Nucl Med. 2015;56(3):339–46.

Article  CAS  PubMed  Google Scholar 

Gabr A, Riaz A, Johnson GE, Kim E, Padia S, Lewandowski RJ, et al. Correlation of Y90-absorbed radiation dose to pathological necrosis in hepatocellular carcinoma: confirmatory multicenter analysis in 45 explants. Eur J Nucl Med Mol Imaging. 2021;48:580–3.

留言 (0)

沒有登入
gif